Cancer Genetics Partners With ArcherDX To Offer Archer NGS Assays As A Sequencing Service For Biotech And Pharma

BOULDER, Colo.--(BUSINESS WIRE)--ArcherDX, Inc., a leader in NGS-based gene fusion detection, has announced that Cancer Genetics, Inc., (CGI) has become a Certified Service Provider of Archer® FusionPlex® NGS assays. Additionally, CGI plans to use Archer VariantPlex^TM assays to identify copy number variants (CNVs) and point mutations in tumor samples and will be testing these assays in cell-free variant detection.

With headquarters in New Jersey and locations in North Carolina, California, India and China, CGI actively supports biopharma with genomics-based, comprehensive biomarker assessment technologies and services, including markers for immuno-oncology.

Dr. Jason Myers, CEO of ArcherDX, highlighted the importance of having an international network of testing labs to support clinical trials services. “Our biopharma partners look at the market from a global perspective. Given the nature of cancer as a genetic disease and the varying incidence rates in different ethnic groups, it is important to be able to use genomic approaches to identify and enroll patients from around the world and integrate our information with other clinical and genomic features.”

Dr. Rita Shaknovich, Group Medical Director of CGI, elaborated, “There is a global demand to support clinical trials, especially in the areas of tyrosine kinase inhibitor (TKI) development, as the relevance of new gene fusions is linked to potential positive clinical outcomes. ArcherDX is the established leader in modern gene fusion detection, such as NTRK fusions, which are found in a broad range of cancers including adenocarcinomas, high-grade gliomas, pilocytic astrocytomas and leukemias. We are thus pleased to provide their assays to support clinical trials and other services to our global biopharma partners.”

CGI offers a comprehensive range of laboratory services to support biomarker and companion diagnostics strategies and has a strong network of key opinion leaders around the world. By combining strengths in biomarker and diagnostic testing with established collaborations with leading hospitals and medical centers, CGI offers biopharma partners innovative technology and patient insight.

About ArcherDX

ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry and easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance. Complemented by the Archer suite of bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.

ArcherDX is headquartered in Boulder, Colorado.

Archer Certified Service Provider Program

The Archer Certified Service Provider Program is a partnership forged between ArcherDX and participating laboratories. These collaborative efforts are the beginning of ongoing relationships that continue far past the certification process. Benefits of the program to providers are increased referrals and endorsements, early access to new ArcherDX technologies and co-branding with ArcherDX, including listing on ArcherDX’s list of providers.

Note: Archer kits and analysis software are for research use only and not for use in diagnostic procedures.

http://archerdx.com

Archer®, FusionPlex®, VariantPlex™ and AMP™ are trademarks of ArcherDX, Inc.

About Cancer Genetics Incorporated

Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The company has established strong clinical research collaborations with major cancer centers including Memorial Sloan Kettering Cancer Center, Cleveland Clinic, Mayo Clinic, Keck School of Medicine of USC, and the US National Cancer Institute.

CGI offers laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states, including New York.

http://cancergenetics.com